Ignite Creation Date:
2024-05-06 @ 3:55 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04800185
Status:
COMPLETED
Last Update Posted:
2024-02-02
First Post:
2021-03-05
Brief Title:
Characterizing Skin Microbiome Change in Atopic Dermatitis
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
Characterizing Skin Microbiome Change in Atopic Dermatitis Patients After Targeted Topical Treatment Using Crisaborole Ointment
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atopic dermatitis AD also known as eczema is an inflammatory disease of the skin affecting a large proportion of the pediatric and adult patient population Chronic itching and eczematous lesions lead to a high burden of disease and associated patient morbidity with higher infection rates emotional stress and associated psychological disease The microbiome community contributes to human health through several mechanisms Current research suggests that derangements in the normal microbiota may lead to inflammatory bowel disease allergy and metabolic syndromes Specific to dermatology new literature has demonstrated that changes in the microbiome may play a role in the development of atopic dermatitis
With this study the investigators hope to characterize the baseline atopic dermatitis skin microbiome and monitor the evolution of the participants skin microbiome during and after treatment with anti-inflammatory topical medications specifically the Food and Drug Administration FDA-approved phosphodiesterase inhibitor crisaborole ointment 2 Eucrisa
With this study the investigators hope to characterize the baseline atopic dermatitis skin microbiome and monitor the evolution of the participants skin microbiome during and after treatment with anti-inflammatory topical medications specifically the Food and Drug Administration FDA-approved phosphodiesterase inhibitor crisaborole ointment 2 Eucrisa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None